Related Experiment Video

Updated: Jun 14, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

17.7K

Direct Out-of-Pocket Costs of Nirsevimab vs. Palivizumab during the First Respiratory Syncytial Virus Season: A

Ki Wook Yun1,2, Dayun Kang1

  • 1Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.

Infection & Chemotherapy
|May 9, 2025
PubMed

Insights

New long-acting antibody nirsevimab offers season-long respiratory syncytial virus (RSV) protection for infants. It may be more cost-effective than palivizumab, especially for babies born during specific months.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) poses a significant health risk to infants.
  • Current prevention with palivizumab (monoclonal antibody) involves a multi-dose regimen.
  • Palivizumab's cost varies significantly based on remaining season and infant weight.

Purpose of the Study:

  • To compare the cost-effectiveness of nirsevimab versus palivizumab for infant RSV prevention.
  • To evaluate nirsevimab as a single-dose, long-acting monoclonal antibody option.
  • To inform policy decisions regarding national immunization programs for RSV.

Main Methods:

  • Comparative cost analysis of two monoclonal antibodies for RSV prevention.
  • Inclusion of health insurance costs and infant weight/seasonality factors.
  • Economic evaluation based on single-dose nirsevimab vs. five-dose palivizumab.

Main Results:

  • Nirsevimab provides season-long RSV protection with one dose.
  • Nirsevimab's cost ranges from 435,000-600,000 KRW.
  • Palivizumab's cost ranges from 47,260-642,000 KRW.
  • Nirsevimab may be more economical for infants born between April and November.

Conclusions:

  • Nirsevimab presents a potentially more economical option for infant RSV prevention.
  • Policy adjustments are recommended to integrate nirsevimab into national immunization programs.
  • Ensuring equitable access to RSV protection for all infants is crucial.

Keywords:
CostNirsevimabPalivizumabRespiratory syncytial virus

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

Related Concept Videos

Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...